US FDA Advisory Panel Backs Innovative Multi-Cancer Blood Test
U.S. health advisers voted to support Grail's Galleri blood test for multi-cancer early detection, balancing potential benefits against accuracy concerns.
Federal health advisers in the United States have voted to support an innovative blood test designed to detect signs of multiple cancer types in seemingly healthy individuals, marking a significant milestone for early detection technology.
The "Galleri" test, developed by the company "Grail," does not diagnose cancer directly. Instead, through a single blood draw, it searches for molecular signals indicating the presence of a tumor from a broad list of potential cancers. Patients who receive a positive result are required to undergo clinical follow-up examinations to confirm a diagnosis.
The advisory committee of the U.S. Food and Drug Administration (FDA) voted in favor of the test by a margin of seven to two, with one abstention. The committee concluded that the DNA-based test offers more potential benefits than risks, such as false security or false alarms.
Expert Warnings and Clinical Risks
Despite the favorable vote, panel members raised numerous questions regarding the technology, emphasizing that further research is necessary. Dr. Victor Van Berkel, a committee member from Kentucky, explained his cautious stance.
"Perhaps my vote is more optimistic than precise," said Van Berkel, highlighting the need for continued studies even if the test achieves widespread public release.
FDA experts and other professionals spent hours debating the potential drawbacks of the technology. Committee members declined to classify the test as definitively effective for "early detection" and established a series of precautions that physicians must communicate to patients. They stressed that the test must be used in addition to standard screening procedures, such as mammograms and colonoscopies, rather than as a replacement.
Future Availability and Industry Impact
Currently, consumers in the United States can purchase the Galleri test privately, typically paying $700 or more out of pocket. Official FDA approval is expected to dramatically expand accessibility by opening the door to insurance coverage from private providers and government health programs.
Representatives for Grail argued before the committee that the test represents a major technological leap because it can detect signals for more than 50 types of cancer, including dozens of tumors that currently lack standard screening options, such as liver and ovarian cancers.
